Precision health should be built on the right reference points.
Your genome, biomarkers, ancestry, and trends all change how health data should be interpreted. Meridian brings these layers together for people in Singapore and Malaysia.
The difference between a sample and your whole story.
Many consumer DNA tests use genotyping arrays that read selected positions across the genome. Whole genome sequencing reads across the genome, giving a more complete foundation for future analysis, re-interpretation, and clinically relevant findings.
Reads selected positions.
Useful for some ancestry and trait reports, but limited by what was chosen for the array. Cannot find variants outside the predetermined list.
Reads across the genome.
Includes regions and variants that arrays may miss. Built as a long-term health record that can be re-analysed as science improves.
Genetic research has not represented everyone equally.
A large share of genetic research has historically been built on people of European ancestry. That can affect how genetic risk, drug response, and biomarker interpretation transfer to Asian and multi-ancestry populations.
Meridian acknowledges these limitations openly. Where ancestry-specific evidence exists, we use it. Where it does not, we say so, and we work with conservative interpretations until better data is available.
Singapore and Malaysia are not one population.
Chinese, Malay, Indian, Eurasian, and mixed-ancestry communities can differ in genetic background, disease prevalence, medication response, and cardiometabolic risk patterns. Meridian is designed to treat that context as part of the product, not as an afterthought.
Your genome is the map. Your biomarkers are the weather.
Your genome changes little over your life. Biomarkers change with sleep, diet, training, stress, disease, medication, and age. Meridian reads the stable layer and the live layer together, so results are interpreted in context.
What Meridian does not claim.
Meridian does not diagnose disease, replace a doctor, or provide emergency medical care. Genetic risk is probabilistic, not destiny. Biomarkers can fluctuate. High-impact findings should be reviewed with a qualified clinician and may require confirmatory testing.